Anti-LAG-3 is emerging as an important clinical antibody in combination with anti-PD-1 based on pre-clinical studies indicating therapeutic syngergy, [54, 55] and is being evaluated currently for adults with recurrent GBM (NCT02658981). Here, LAG3 is linked to glioblastoma.